Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

BACKGROUND: The introduction of combined conventional cytostatics and pathway-specific inhibitors has opened new treatment options for several cancer types including hematologic neoplasia such as leukaemias. As the detailed understanding of the combination-induced molecular effects is often lacking,...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Cell Int
Main Authors: Sklarz, L.-M., Gladbach, Y. S., Ernst, M., Hamed, M., Roolf, C., Sender, S., Beck, J., Schütz, E., Fischer, S., Struckmann, S., Junghanss, C., Fuellen, G., Murua Escobar, H.
Format: Artigo
Language:Inglês
Published: BioMed Central 2020
Subjects:
Primary Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7425054/
https://ncbi.nlm.nih.gov/pubmed/32817744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-020-01431-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items